Advertisement

Reactions Weekly

, Volume 1743, Issue 1, pp 86–86 | Cite as

Eribulin

First report of tumour lysis syndrome: case report
Case report
  • 18 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

First published case report

A middle aged woman [exact age at the time of reaction onset not stated] developed tumour lysis syndrome (TLS) following treatment with eribulin for metastatic uterine leiomyosarcoma.

The woman presented to the emergency department due to right upper quadrant pain. One year before the presentation, she was diagnosed with leiomyosarcoma of the uterus and underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy. Her post-operative course was uncomplicated, and she had received adjuvant chemotherapy with docetaxel, gemcitabine and pegfilgrastim. On presentation to the emergency department, various laboratory and diagnostic investigations were performed, which revealed bulky metastatic recurrence. Her abdominal pain was treated with...

Reference

  1. Pabon C, et al. Tumour lysis syndrome following eribulin for metastatic uterine leiomyosarcoma. BMJ Case Reports 11: No. 1, Dec 2018. Available from: URL: http://doi.org/10.1136/bcr-2018-224576 - USA

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations